

## Living Cell Technologies Limited

**ABN:** 14 104 028 042  
**ASX:** LCT  
**OTCQB:** LVCLY

Living Cell Technologies Limited  
Level 23, Rialto South Tower  
525 Collins Street  
Melbourne, Victoria 3000  
AUSTRALIA  
Ph: +61 422 180 317  
Email: [brad@lctglobal.com](mailto:brad@lctglobal.com)  
Web: [www.lctglobal.com](http://www.lctglobal.com)  
ABN: 14 104 028 042

19 June 2023

## Update on NTCELL Project for Parkinson's disease

Melbourne, Australia, 19 June 2023 - Living Cell Technologies Limited (ASX: LCT) (OTC: LVCLY) ("LCT" or "the Company") is pleased to provide the following update on the NTCELL clinical trial program for Parkinson's disease ('PD').

In January of 2021, LCT engaged NZeno Limited ('NZeno') to breed and maintain pigs to provide porcine choroid plexus tissue for the manufacture of NTCELL to be used in the Company's upcoming third clinical trial in people with PD. NZeno maintains the only herd derived from designated pathogen-free (DPF) pigs found on New Zealand's sub-Antarctic Auckland Islands.

LCT has previously manufactured NTCELL for the purpose of conducting the first and second clinical trials. The choroid plexus tissue for the previous two clinical trials of NTCELL, in 2012 and 2015, were obtained from pigs in this herd.

NZeno has now finalised all agreed aspects of LCT's dedicated pig herd facility and surgical facility at NZeno's location in Invercargill, New Zealand. The facilities have been built exclusively for LCT and entitle the Company to maintain and manage its own source of DPF pigs required for the manufacture of GMP grade NTCELL for use in the third clinical trial.

### **Scientific Review of NTCELL Clinical Trial Protocol**

LCT has commenced a scientific review of the NTCELL clinical trial protocol and development plan to assess recommendations proposed by Professor Carolyn Sue to improve the therapeutic value of NTCELL.

As an internationally recognised clinician-scientist, and a leader in the field of Parkinson's disease, Professor Sue is leading the review. LCT has engaged the assistance of a multi-disciplinary panel of scientific experts to advise upon aspects of a revised NTCELL project.

During the time of the scientific review, LCT has enacted a temporary pause to the maintenance of the porcine herd to minimise unnecessary ongoing costs during the time in which the choroid plexus tissue is not required. The herd will be built up again in 2024 following the scientific review, which will encompass adjustments to the clinical trial protocol and plans to engage clinical trial partners. Manufacture of NTCELL for the third clinical trial will recommence following the scientific review.

### **NTCELL Scientific Advisory Board**

LCT has appointed an esteemed scientific advisory board to provide ongoing expert advice for the successful development of the NTCELL project. Consultants on the advisory board share their opinions on matters

concerning the NTCELL program following their review of prior clinical trial data achieved from the first and second NTCELL clinical trials. Their opinions will shape the scientific review being undertaken by LCT. Consultants on the NTCELL advisory board are:

**Professor Glenda Halliday**, of The University of Sydney

Professor Halliday is a neuroscientist and research neuropathologist specializing in neurodegeneration.

Professor Halliday was recently acknowledged in the 2023 King's Birthday Honours List and awarded the prestigious Companion of the Order of Australia (AC), for "*eminent achievement and merit of the highest degree in service to Australia or to humanity at large*".

She is a Research Fellow in the National Health and Medical Research Council (NHMRC) and Australian Research Council (ARC) systems since 1988, attesting to the quality of her research ideas and ability to prosecute them. She was appointed Professor of Medicine (2003) then of Neuroscience (2008), then NHMRC Senior Principal Research Fellow (2010) at the University of New South Wales and is now a NHMRC Leadership Fellow located at the University of Sydney until 2025. Professor Halliday has successfully worked with many Australian and international researchers on important scientific questions on Parkinson's disease, alcohol toxicity, dementia with Lewy bodies, frontotemporal dementias, and motor neurodegenerative diseases.

Her research has directly influenced clinical practice by providing the evidence base for understanding the pathologies underlying neurodegenerative diseases, clarifying the trajectory of these diseases over time and exploring any potential variability.

**Professor Robert Kapsa**, of RMIT University

Professor Kapsa is a Molecular and (Stem) Cell Biologist with 26 years' basic research experience focused on developing autologous regenerative therapies for muscle disorders.

Professor Kapsa is the standing inaugural Professor, Biofabrication and Tissue Engineering at RMIT University in Melbourne. He received his PhD in 1996 on mitochondrial polymorphisms in human disease from the University of Melbourne Department of Medicine. He has published over 131 peer-reviewed research papers, including three book chapters and one book focused on nerve and muscle biology and medicine.

Professor Kapsa's experience ranges from tissue regeneration, molecular biology, gene therapy, biochemistry and he has been the lead investigator on a number of national and international (USA and Europe) projects dealing with use of polymers for tissue engineering, particularly for nerve and muscle, and gene editing-based autologous regenerative medicine solutions for hereditary nerve and muscle dysfunction (particularly DMD and more recently, FSHD).

Robert also has Advisory Board responsibilities for ISN Psychology, FSHD Global Research Foundation.

**Professor Ali Abbas**, of Scimita Ventures and the University of Sydney

Ali Abbas is a Co-Founder and Director of Scimita Ventures where he focuses on technical and business strategy. In addition to his role at Scimita, Ali is a Professor of Chemical Engineering at the University of Sydney in the School of Chemical and Biomolecular Engineering where he serves as Deputy Head of School and is Founding Director of the Waste Transformation Research Hub, a national centre aimed at addressing the waste industry's research and technological challenges. Ali was recently appointed by Circular Australia as Australia's first Chief Circular Engineer. Ali's is founding chair of the Australian Circular Economy Conference.

Ali received both his Bachelors and PhD in Chemical Engineering from the University of Sydney. He has held previous academic appointments at Singapore and visiting professor positions at several institutions including Harvard.

Ali has 20 years' experience in the field of Process Systems Engineering, with expertise in process intensification and design, techno-economic feasibility, process scale-up / optimal operation, with applications spanning biotechnology, biomedical systems to low-emissions technologies and circular economy. He has published more than 140 papers in international scientific and engineering journals.

Ali provides consultations to industry and government, and is active in commercialization activities, developing breakthrough deep technologies across multiple industry sectors in his capacity as company Founder and Director.

**Associate Professor Tina Soulis**, of Alithia Life Sciences

Dr Tina Soulis has over 27 years' experience working in the healthcare (pharmaceuticals and devices), biotechnology, academic research, clinical research and management sectors. She has held senior roles, including CEO of a Contract Research Organization, Director of an ASX200 company, VP of Clinical Strategy and Development with a biotechnology company and now, Founder and Director of her own clinical consultancy company, Alithia Life Sciences ('Alithia').

Alithia is an Australian owned clinical research consultancy launched to support and assist pharmaceutical, biotechnology, device companies and institutional research groups undertaking their project in the Australian region and beyond. Tina and Alithia have over 25 years of operational expertise and industry experience in various therapeutic areas including, first in human studies, devices, endocrinology, oncology, neurology, gastroenterology, rare and paediatric diseases and vaccines. Tina has expertise in the academic, commercial and biotechnology settings and can support projects from Phase I through to Phase III and FDA approval processes.

**Associate Professor Thomas Kimber**, of The Royal Adelaide Hospital and University of Adelaide

Dr Kimber graduated from the University of Adelaide in 1989 and then undertook physician training at the Royal Adelaide Hospital. He completed his Neurology advanced training at the Royal Adelaide Hospital, Sir Charles Gairdner Hospital in Perth, and the Royal Free Hospital in London. His PhD, which concerned the effects of pallidotomy surgery on motor function in Parkinson's disease, was awarded by the University of Adelaide in 2008.

Dr Kimber is a senior consultant neurologist at the Royal Adelaide Hospital, where he leads the Movement Disorders Service, and a Clinical Associate Professor in the Department of Medicine at the University of Adelaide. His research work focusses on the development of novel therapeutic approaches for the management of Parkinson's disease and related disorders.

Dr Kimber is the immediate Past President of the Movement Disorders Society of Australia and New Zealand.

**This announcement has been approved for release to ASX by the LCT Board of Directors.**

**END**

**For further information:** [www.lctglobal.com](http://www.lctglobal.com)

**Corporate and Media Enquiries**

Brad Dilkes  
Non-executive Director  
Mobile: +61 422 180 317  
[brad@lctglobal.com](mailto:brad@lctglobal.com)

**About Living Cell Technologies**

Living Cell Technologies Limited is a biotechnology company focused on discovering and developing novel treatments for debilitating conditions such as diabetes and Parkinson's disease. The Company is incorporated in Australia, with its operations based in Australia and New Zealand. LCT is listed on Australian (ASX: LCT) and US (OTCQB: LVCLY) stock exchanges.

For more information visit [www.lctglobal.com](http://www.lctglobal.com) or follow @lctglobal on Twitter, Facebook or LinkedIn.

**Forward-looking statements**

This document may contain certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "probable", "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, or expected. LCT is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.